Skip to content

Medication Adherence Enhancement in Heart Transplant Recipients

Medication Adherence Enhancement in Heart Transplant Recipients: a Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00843960
Enrollment
150
Registered
2009-02-13
Start date
2009-02-28
Completion date
2013-12-31
Last updated
2009-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication Adherence, Rejection, Self Management

Brief summary

Medication-related non-adherence increases the risk of rejections and associated graft loss after solid organ transplantation. A randomized controlled intervention will use adherence enhancing strategies out of a larger sample of 300 heart transplant recipients. Non-Adherence will be assessed by patients' self-report and based on immunosuppression level. All non-adherent patients will be randomly designed to either intervention or control group. Multi-module interventions include patient education, electronic medication event monitoring, and a combined behavior and symptom management. Longitudinal follow-up is envisioned after initial intervention.

Interventions

BEHAVIORALbehavioral adaptation and symptom management

behavioral adaptation and symptom management

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
Hannover Medical School
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* all eligible patients with follow-up at our outpatient clinic * written informed consent * sufficient German language skills to read and answer a battery of questionnaires * \> 18 years * minimum 6 mts post HTX

Exclusion criteria

* illiteracy

Design outcomes

Primary

MeasureTime frame
Occurrence of adverse events (composite endpoint)at month 60

Secondary

MeasureTime frame
Adherence behavior measurement variables from MEMS systemfirst 3 month
Immunosuppression levelMonth 3, 12 and 60
All individual components of the composite endpoint occurence of adverse eventsat month 60

Countries

Germany

Contacts

Primary ContactChristiane Kugler, PhD
kugler.christiane@mh-hannover.de++49.511.532

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026